diaDexus moves CAD (coronary artery disease) risk test closer to the US:
This article was originally published in Clinica
Executive Summary
diaDexus is pushing ahead with efforts to market in the US its PLAC blood test for predicting coronary artery disease (CAD) risk, after submitting a 510(k) application for the product to the FDA. The test provides a quantitative measurement of lipoprotein-associated phospholipase A2, or Lp-PLA2, a marker believed to be a risk factor for coronary heart disease. Since a significant proportion of individuals who suffer a heart attack have no previous signs or symptoms of coronary heart disease, such as elevated cholesterol, there is clearly a need for additional tests to accurately identify those at risk, says Patrick Plewman, the San Francisco, California's firm's CEO.
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.